A comparison of the removal of parvovirus B19 and model parvoviruses from plasma products by virus filtration

Similar documents
EMEA WORKSHOP ON VIRAL SAFETY OF PLASMA-DERIVED MEDICINAL PRODUCTS WITH PARTICULAR FOCUS ON NON-ENVELOPED VIRUSES. 13 September 2000 REPORT SUMMARY

Solvent-Detergent for Virus Inactivation: An Evolving Technology Peter Roberts Bio Products Laboratory Elstree, UK

Ensuring Compliance: Regulatory guidance for virus clearance validation

Meta Analysis of Virus Partitioning in Fractionation

Viral clearance (inactivation and. Part 3a, Plasma and Plasma Products (Heat and Solvent/Detergent Treatments)

WHO Parvovirus B19 Genotype Panel

Plasma for fractionation: South African Plasma Requirements

Hepa%%s E Virus Is it a Concern?

RETROSPECTIVE EVALUATION OF LOW PH VIRAL INACTIVATION AND VIRAL FILTRATION DATA FROM MULTIPLE COMPANY COLLABORATION

Source Plasma Safety

Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma Products

Reflection paper on viral safety of plasma-derived medicinal products with respect to hepatitis E virus

Objectives. Methods. Results. Economic

For purification of viral DNA and RNA from a wide range of sample materials

UvA-DARE (Digital Academic Repository) Viral safety of blood and plasma products Terpstra, F.G. Link to publication

Magdy El Ekiaby, MD Shabrawishi Hospital BTC & HTC Cairo, Egypt

Pathogenreduktion mittels UVC-Licht: Entwicklung des THERAFLEX UV-Plättchen-Systems

Viral Clearance Strategies for Biopharmaceutical Safety

Diagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)

VIRUS VALIDATION STUDIES: THE DESIGN, CONTRIBUTION AND INTERPRETATION OF STUDIES VALIDATING THE INACTIVATION AND REMOVAL OF VIRUSES

MagCapture Exosome Isolation Kit PS Q&A

Screening donors and donations for transfusion transmissible infectious agents. Alan Kitchen

INDONESIAN EXPERIENCE IN PRODUCING MINIPOOL CRYOPRECIPITATE. Yuyun SM Soedarmono

Stability of native, lyophilized and inactivated standards

Reflection paper on viral safety of plasma-derived medicinal products with respect to Hepatitis E virus

Draft Agreed by Biologics Working Party December Draft Agreed by Blood Products Working party December 2010

The Immune Response to Parvovirus B19 Exposure in Previously Seronegative and Seropositive Individuals

Non-competitive Internal Control Concept for PCR-based Qualitative Assays

HEV Assay Development Update

Pathogen Reduction/Inactivation KABB Annual Meeting Elpidio Pena, MD, MA Norton Healthcare Transfusion Services

Product Monograph. Key Scientific Information

(DNA) Real-time PCR. Exicycler 96 Rotor-Gene Q/6000 PCR

Purification of viral nucleic acid from serum, plasma, cell-free biological fluids MACHEREY- NAGEL

Zpracování lidské plazmy


WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA

National Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands. TransMed conference Bhopal 18 November 2016

Parvovirus B19 Mixed Titer Performance Panel PVP201

NRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens

October 26-30, 2003 Salt Lake City, Utah

Evaluation of run controls for cobas 6800 MPX and HEV assay

Human Hepatitis B Immunoglobulin, solution for intramuscular injection.

Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012

Routine NAT-screening for West Nile Virus Infections in Germany: Being prepared

PHARMACOPOEIA MONOGRAPH

In previous articles of this viral inactivation. Part 6, Inactivation Methods Grouped by Virus

AccuVert HBV Seroconversion Panel PHM941(M) ( )

Pathogen Safety and BSE / variant CJD

QUALITY CONTROL Infectious Disease

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

QUANTITATION OF HEPATITIS B VIRUS DNA IN PLASMA USING A SENSITIVE COST-EFFECTIVE IN-HOUSE REAL-TIME PCR ASSAY

الحترمونا من خري الدعاء

Application of μmacs Streptavidin MicroBeads for the analysis of HIV-1 directly from patient plasma

Human Normal Immunoglobulin, solution for intramuscular injection.

Using Donor Human Milk in Extremely Premature Infants

Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.

Assays to Address Emerging Threats to Blood Safety

Experience with Standardisation of Blood Virology NAT. Clare Morris Division of Retrovirology National Institute for Biological Standards and Control

Laboratory Diagnosis of Viral Infections. G. Jamjoom 2005

Introductory Virology. Ibrahim Jamfaru School of Medicine UHAS

Viruses challenge biopharmaceutical

CSL Behring LLC Albuminar -25 US Package Insert Albumin (Human) USP, 25% Revised: 01/2008 Page 1

Hepatitis E and the English blood supply

Official Journal of the European Communities COMMISSION

Rama Nada. - Malik

1. Virus 2. Capsid 3. Envelope

DATA SHEET. Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA.

HEMOFIL M Antihemophilic Factor (Human), Method M, Monoclonal Purified Nanofiltered

HIV-1 Viral Load Real Time (RG)

19 2 Viruses Slide 1 of 34

AccuSet HBV Worldwide Performance Panel

Human Zoster Immunoglobulin, solution for intramuscular injection.

Viruses. Picture from:

Viral structure م.م رنا مشعل

Human diagnostics. Better be Sure: Quantify HDV & HBV viral load. RoboGene product family

SECTION 25-1 REVIEW STRUCTURE. 1. The diameter of viruses ranges from about a. 1 to 2 nm. b. 20 to 250 nm. c. 1 to 2 µm. d. 20 to 250 µm.

Viral Hepatitis Diagnosis and Management

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

NEW ZEALAND DATA SHEET

the world and viruses

Microbiology Chapter 7 Viruses

Keeping the Blood Supply Safe Current and Future Strategies. Marissa Li, MD

For Research Use Only Ver

Prevention of infection 2 : immunisation. How infection influences the host : viruses. Peter

Keeping blood transfusions safe:

Controls & Calibrators. Disease Quality Controls

The Alphabet Soup of Viral Hepatitis Testing

Chapter 13 Viruses, Viroids, and Prions. Biology 1009 Microbiology Johnson-Summer 2003

Update on THERAFLEX UV-Platelets: a novel system for pathogen reduction of platelets

Cangene Corporation Page 1 of 12

Evaluating novel cell substrates for use in vaccine manufacture WCBP, January 14, 2009

(DNA) Real-time PCR. Exicycler 96 Rotor-Gene Q/6000 PCR

The Technical Aspects of Pathogen Testing in Canada. Nancy Angus Canadian Blood Services Director, Testing

Original Articles SAFETY OF BLOOD AND PLASMA DERIVATIVES: PATHOGEN REDUCING TECHNOLOGIES

NEW ZEALAND DATA SHEET

PRODUCT MONOGRAPH. HepaGam B

Starting with MICROBIOLOGY

donors and collecting blood and plasma in for-profit or a not for profit environment

DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE

Transcription:

A comparison of the removal of parvovirus B19 and model parvoviruses from plasma products by virus filtration Shirley Stagg, Samantha Fernando, Amy Shackell, Peter Roberts, Joan Dalton Bio Products Laboratory, Elstree UK

A comparison of the removal of parvovirus B19 and model parvoviruses from plasma products by virus filtration Shirley Stagg, Samantha Fernando, Amy Shackell, Peter Roberts, Joan Dalton Bio Products Laboratory, Elstree UK

Viruses of Concern Virus Envelope Nucleic acid Size (nm) HIV + RNA 80-100 WNV + RNA 80-100 HBV + DNA 40-50 HCV + RNA 40-50 HAV - RNA 25-30 B19 - DNA 18-24

Parvovirus B19 High prevalence High levels of viraemia Can be asymptomatic Mini pool screening to reduce contamination (<10 4 IU/ml) <10 4 IU/ml may not be infective

Animal models Canine parvovirus (CPV) Porcine parvovirus (PPV) Minute virus of mice (MVM) Bovine parvovirus (BPV)

Virus inactivation / removal techniques Clearance technique B19 Susceptibility Animal model Solvent / detergent - - Pasteurisation +++ ++ Dry heat treatment +++ ++ Low ph +++ +/- Filtration??

Parvovirus filtration

Virus Product Filtration Protocol 0.1µm filtration (to remove aggregates) Spiked Product ~100 ml Spiked load sample Load VIRUS FILTRATION Collected in fractions Filtrate

B19 Measurement of B19 and CPV Qiagen QIAamp MinElute Virus Spin Extraction Kit Roche LightCycler Parvovirus B19 Quantification Kit CPV Plaque assay (A-72 cells) TCID 50

High-purity FIX Step Polio-1 HAV CPV B19 Planova 15N >5.6 >6.0 3.2 >7.2

IVIG Step EMC HAV B19 CPV Pall Ultipor DV20 >4.8 >4.8 6.0 3.2

Coagulation factors A B C B19 in 11.8 log 10.6 log 10.4 log Planova 15N B19 out <4.6 log <4.7 log 5.0 log LRV >7.2 >5.9 5.4

Coagulation factors A B C CPV in 6.3 log 6.3 log 6.8 log Planova 15N CPV out 3.1 log 2.2 log 3.1 log LRV 3.2 4.1 3.7

Robustness of parvovirus removal from IVIG Filter Pall Ultipor DV20 filter Parameters Pressure (Bar) Protein concentration (mg/ml) ph Load (L/m 2 )

Effect of pressure on DV20 filtration 7 6 Log Virus Removal 5 4 3 2 1 B19 3 Bar B19 3.3 bar CPV 3 bar CPV 3.3 bar 0 Fr 1 Fr 2 Fr 3 Fr 4

Effect of ph on DV20 filtration 6 Log Virus Removal 5 4 3 2 1 B19 ph 4.4 B19 ph 5.1 CPV ph 4.4 CPV ph 5.1 0 Fr 1 Fr 2 Fr 3

Effect of protein concentration on DV20 removal 7 6 Log Virus Removal 5 4 3 2 1 B19 0g/l B19 10 g/l B19 14 g/l CPV 0g/l CPV 10g/l CPV 14 g/l 0 Fr 1 Fr 2 Fr 3 Fr 4

B19 vs CPV Removal of B19 higher than CPV Removal is consistent Why?

Factors to be considered: Is it just CPV? Size of particles Presence of antibodies Aggregation B19 plasma sample Filter

Removal of parvovirus from buffer by DV20 filtration 6 Log Virus Removal 5 4 3 2 1 B19 CPV PPV 0 Fr 1 Fr 2 Fr 3

PPV removal Filter BPL Study External Study DV20 3.1 Buffer 4.8 IgG

Size of virus particles? No obvious difference in size of particles 18 24 nm in size B19 has smoother surface, may even be slightly smaller Difference in source PPV & CPV - tissue culture grown B19 from +plasma donation

Presence of B19 antibodies

Effect of protein concentration on DV20 removal 7 6 Log Virus Removal 5 4 3 2 1 B19 0g/l B19 10 g/l B19 14 g/l CPV 0g/l CPV 10g/l CPV 14 g/l 0 Fr 1 Fr 2 Fr 3 Fr 4

12 10 B19 Log copies/ml 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Donation ID

IgM measurement Biotrin Parvovirus B19 IgM Enzyme Immunoassay Kit Cut off value: 0.344 Donor 01 Donor 08 Donor 13 Donor 14 Donor 15 Donor 16 0.090 0.072 0.058 0.062 0.060 0.905

Aggregation

Aggregation of virus stocks No loss of B19 over 0.1µm pre-filtration of stock Aggregation also assessed by Planova 35N filtration

Planova 35N B19 in A 9.4 log B 8.3 log 35N B19 out 9.0 log 7.8 log LRV 0.4 0.5

B19 plasma

Influence of B19 spike Removal of B19 from buffer by DV20 filtration 6 Log Virus Removal 5 4 3 2 1 Donor 01 Donor 14 Donor 15 0 Fr 1 Fr 2

Filter type

Preliminary data from alternative filters Filter Virus Solution A B Log Virus Removal B19 IgG 5.3 CPV PPV Buffer >5.8 IgG Buffer >4.6 >4.3 >4.3 >5.5 >7.3 B19 3.1 CPV Buffer 1.7 PPV 1.9

Regulatory Question the applicant has shown that this filter is less effective against canine parvovirus which is the same size and shape as human B 19. Does the applicant have any theories as to why the two viruses were not similarly cleared by the filter?

Conclusions/theories B19 is removed to a greater extent than CPV or PPV Viruses are the same size Virus stocks are not aggregated Could not demonstrate abs Different B19+ plasma samples gave similar results B19 may bind to some other factor in plasma e.g. globoside? The use of animal parvoviruses represents a true worst case challenge to filters Removal influenced by virus stocks, solution being filtered, filter type

Thankyou Biosafety group at BPL Anchal Johni

Company Filter Construction material Claims (LRV) Planova 15N >6.2 parvovirus >6.7 polio Asahi- Kasei Planova 20N Cuprammonium Regenerated Cellulose >4.3 parvovirus >5.4 EMC Planova 35N >5.9 BVDV >7.3 HIV Millipore Viresolve NFP Modified PVDF >4 φx-174 bacteriophage Viresolve NFR Polyether Sulphone >6 Retrovirus Viresolve Pro Polyether Sulphone [double layer] >4 MVM Pall Ultipor DV20 Modified PVDF [triple layer] >3 PP7 bacteriophage >6 PR772 bacteriophage Ultipor DV50 >6 PR772 bacteriophage Sartorius Virosart CPV Polyether Sulphone [double layer] >4 PR772 bacteriophage >6 Retrovirus Manufacturer s literature + Burnouf T & Radosevich, M., Haemophilia (2003), 9, 24-37